

#### WHI Follow-Up Dataset

## **HRT and CaD Unblindings Prior to Study Closure**

Data File: unbl\_ct\_pub File Date: 07/20/2007 Structure: Multiple rows per participant Population: HT & CaD participants

**Participant ID** 

Variable # 1 Usage Notes: none

Sas Name: ID

Sas Label: Participant ID Categories: Study: Administration

Study for which unblinding occurred

Variable # 2 Usage Notes: none

Sas Name: UNBLSTDY

Sas Label: Study for which unblinding occurred Categories: Study Interventions: Unblinding

 Values
 N
 %

 1
 HRT Unblinding
 4,743
 98.8%

 2
 CaD Unblinding
 58
 1.2%

4,801

Unblinding sequence within study

Unblinding sequence within study for the participant

Variable # 3 Usage Notes: none

Sas Name: UNBLSEQ

Sas Label: Unblinding sequence within study

Categories: Study Interventions: Unblinding

 N
 Min
 Max
 Mean
 Std Dev

 4801
 1
 5
 1.12622
 .39357

**Unblinding days since CT randomization** 

Variable # 4 Usage Notes: none

Sas Name: UNBLDAYS

Sas Label: Unblinding days since CT randomization

Categories: Study Interventions: Unblinding

 N
 Min
 Max
 Mean
 Std Dev

 4801
 2
 3528
 720.11456
 595.68701

**Unblinding days since CaD randomization** 

Variable # 5 Usage Notes: none

Sas Name: UNBCADDY

Sas Label: Unblinding days since CaD randomization

Categories: Study Interventions: Unblinding

N Min Max Mean Std Dev

3043 -733 3155 350.85902 605.24216

Unblinding due to study medication adverse effects

Variable # 6 Usage Notes: none

Sas Name: ADVERSE

Sas Label: Unblinding due to study medication adverse effects

Categories: Study Interventions: Unblinding

 Values
 N
 %

 0
 No
 2,595
 54.1%

 1
 Yes
 2,206
 45.9%

 4,801
 4,801

Page 1 of 3 07/20/2007



WHI Follow-Up Dataset

## **HRT and CaD Unblindings Prior to Study Closure**

Data File: unbl\_ct\_pub File Date: 07/20/2007 Structure: Multiple rows per participant Population: HT & CaD participants

Unblinding due to overdose

Variable # 7

Sas Name: OVERDOSE

Sas Label: Unblinding due to overdose

**Values** N % 0 No 4,789 99.8% Yes 12 0.2% 4,801

Usage Notes: none

Categories: Study Interventions: Unblinding

Unblinding due to other medical problem

Variable # 8

Sas Name: OTHERMED

Sas Label: Unblinding due to other medical problem

**Values** N % No 83.9% 0 4,030 1 Yes 771 16.1% 4,801

Usage Notes: none

Categories: Study Interventions: Unblinding

Gynecologist or designated physician consulted

Variable # 9

Sas Name: GYNCNSL

Sas Label: Gynecologist or designated physician consulted

**Values** % No 158 3.3% 96.7% 1 Yes 4,643 4,801

Usage Notes: none

Categories: Study Interventions: Unblinding

Attempted to treat condition without unblinding

Variable # 10

Sas Name: TREAT

Sas Label: Attempted to treat condition without unblinding

Values % 0 No 2,839 59.1% 1,962 40.9% Yes 4,801

Usage Notes: none

Categories: Study Interventions: Unblinding

07/20/2007 Page 2 of 3



### WHI Follow-Up Dataset

# **HRT and CaD Unblindings Prior to Study Closure**

Data File: unbl\_ct\_pub File Date: 07/20/2007 Structure: Multiple rows per participant Population: HT & CaD participants

# Order to unblind given by gynecologist/physician

Order to unblind given by gynecologist or designated physician

eraci to anomia given by gymodelegict or accignated physicial

Sas Name: GYNORDER

Variable # 11

Sas Label: Order to unblind given by gynecologist/physician

 Values
 N
 %

 0
 No
 259
 5.4%

 1
 Yes
 4,542
 94.6%

 4,801
 4,801

Usage Notes: none

Categories: Study Interventions: Unblinding

### Order to unblind given by PI

Order to unblind given by Clinical Center Principal Investigator

Variable # 12

..........

Sas Name: PIORDER

Sas Label: Order to unblind given by PI

 Values
 N
 %

 0
 No
 3,842
 80.0%

 1
 Yes
 959
 20.0%

 4,801

Usage Notes: none

Categories: Study Interventions: Unblinding

Page 3 of 3 07/20/2007